Showing 3911-3920 of 4045 results for "".
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Launch of TrueLipids® Made with Zemea® Propanediolhttps://practicaldermatology.com/news/20140320-launch_of_truelipids_made_with_zemea_propanediol/2459307/Cheryl Lee, MD, Sensitive Skin Care, is soon launching its patent-pending line, TrueLipids® therapeutic products. TrueLipids, now made with Zemea® is designed to repair disrupted skin barriers and promote lipid production, while being cosmetically friendly to the skin. This new li
- Foamix, Ltd. Will Present Phase II Results for Topical Minocycline at Upcoming Conferencehttps://practicaldermatology.com/news/20140227-foamix_ltd_will_present_phase_2_results_for_topical_minocycline_at_upcoming_conference/2459328/Foamix will present the successful results from its Phase II clinical trials with topical minocycline for acne and impetigo at the 34th Annual Cowen & Company Health Care Conference. The pharmaceutical company, which focuses on the development of patented topical foams for de
- Video Intervention May Increase Skin Cancer Diagnosis in Older Menhttps://practicaldermatology.com/news/20140224-video_intervention_may_increase_skin_cancer_diagnosis_in_older_men/2459334/Showing men a video on skin self-examination and skin awareness may help to increase the number of patients who receive whole-body clinical skin examinations (CSEs) from their physicians, which could increase skin cancer diagnosis in older men, according to a study by Monika Jan
- AAD Responds to New York Timeshttps://practicaldermatology.com/news/20140127-aad_sumbits_letter_to_the_editor_to_new_york_times/2459358/In response to The New York Times article “Patients' Costs Skyrocket; Specialists' Incomes Soar” (“Paying Till It Hurts” series, Jan. 19, 2014), the American Academy of De
- DermatologistOnCall Launches Online Platformhttps://practicaldermatology.com/news/20140123-dermatologistoncall_launches_online_platform/2459362/DermatologistOnCall® has launched its online platform, allowing dermatologists to efficiently diagnose and prescribe a treatment plan for patients with more routine conditions via an online portal, while reserving in-office appointments for more severe cases. After a patient registers, dermatologist
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- Rosacea Survey: Emotional Impact of Rosacea as Significant and Visible Signshttps://practicaldermatology.com/news/20140116-rosacea_survey_emotional_impact_of_rosacea_as_significant_and_visible_signs/2459371/The emotional impact of rosacea is often substantial regardless of subtype or severity, according to results of a new survey of 1,675 rosacea patients conducted by the National Rosacea Society. Among survey respondents who suffer from the facial redn